Company intelligence / Profile preview
Hangzhou Adamerck Pharmlabs Inc.
Hangzhou, Zhejiang, Chinaadamerck.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Hangzhou Adamerck Pharmlabs Inc. specializes in the research and development of innovative small molecule pharmaceuticals with over ten proprietary drugs addressing global medical needs. Their lead asset, Adamgammadex Sodium for reversal of neuromuscular blockade, has reached NDA submission in China with positive Phase III results presented at WCA2024. Other pipeline assets target cardiovascular/cerebrovascular diseases and infectious disease.
- Therapeutic areas
- OtherCardiovascularOncologyInfectious Diseases
- Modalities
- Small moleculesNovel patented pharmaceuticals
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Hangzhou Adamerck Pharmlabs Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Adamerck Pharmlabs Inc..